NASDAQ:FLNA Cassava Sciences (FLNA) Stock Price, News & Analysis $1.25 +0.05 (+4.17%) As of 05/20/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cassava Sciences Stock (NASDAQ:FLNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cassava Sciences alerts:Sign Up Key Stats Today's Range$1.19▼$1.3250-Day Range$1.18▼$2.3852-Week Range$1.16▼$4.98Volume401,271 shsAverage Volume405,167 shsMarket Capitalization$60.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer’s disease and related neurodegenerative disorders. Headquartered in Austin, Texas, the company was originally founded as Pain Therapeutics in 1998 and rebranded to Cassava Sciences in 2017. Cassava’s research program centers on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles. The company’s lead drug candidate, simufilam (formerly PTI-125), is a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer’s patients. Simufilam is being evaluated in Phase 2b and Phase 3 clinical trials, with studies conducted across multiple sites in the United States and Australia. Cassava also maintains a pipeline of diagnostics, including exploratory blood-based biomarkers intended to detect pathogenic hallmarks of Alzheimer’s disease at earlier stages. Cassava Sciences is led by President and Chief Executive Officer Remi Barbier, who has guided the company’s strategic transition from pain management to neurodegenerative research. The executive team comprises professionals with backgrounds in neuroscience, clinical development, and regulatory affairs. Cassava’s board includes members with extensive experience in the biotechnology and pharmaceutical industries, supporting the company’s efforts to advance its pipeline and engage with regulatory authorities. With a mission to transform the treatment and diagnosis of Alzheimer’s disease, Cassava Sciences collaborates with academic institutions and contract research organizations to conduct its clinical studies. While the company’s primary activities are centered in North America and Australia, it seeks to establish partnerships and expand its research footprint globally as it progresses its therapeutic and diagnostic programs toward regulatory approval.AI Generated. May Contain Errors. Read More Cassava Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreFLNA MarketRank™: Cassava Sciences scored higher than 2% of companies evaluated by MarketBeat, and ranked 852nd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCassava Sciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Cassava Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.86% of the float of Cassava Sciences has been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 1.15%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for FLNA on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.MarketBeat Follows5 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.60% of the stock of Cassava Sciences is held by insiders.Percentage Held by Institutions38.05% of the stock of Cassava Sciences is held by institutions.Read more about Cassava Sciences' insider trading history. Receive FLNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FLNA Stock News HeadlinesFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateMay 7, 2026 | finance.yahoo.comFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateMay 7, 2026 | globenewswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIMay 5, 2026 | finance.yahoo.comFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIMay 5, 2026 | globenewswire.comFilana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | finance.yahoo.comCassava Sciences to rebrand to Filana TherapeuticsMarch 10, 2026 | seekingalpha.comCassava Sciences Announces Name Change to Filana Therapeutics, Inc.March 10, 2026 | finance.yahoo.comSee More Headlines FLNA Stock Analysis - Frequently Asked Questions How have FLNA shares performed this year? Cassava Sciences' stock was trading at $1.98 at the start of the year. Since then, FLNA stock has decreased by 36.9% and is now trading at $1.25. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:FLNA) released its earnings results on Thursday, May, 7th. The company reported ($0.21) EPS for the quarter. When did Cassava Sciences' stock split? Cassava Sciences shares split on the morning of Thursday, December 21st 2023.The 14-10 split was announced on Thursday, December 21st 2023. The newly issued shares were payable to shareholders after the closing bell on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. How do I buy shares of Cassava Sciences? Shares of FLNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cassava Sciences investors own include Waste Connections (WCN), Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/07/2026Today5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, FLNA's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FLNA Previous SymbolNASDAQ:SAVA CIK1069530 Webwww.filanatx.com Phone512-501-2444Fax512-501-0414Employees20Year Founded1998Profitability EPS (Trailing Twelve Months)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$90.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-53.90% Return on Assets-34.20% Debt Debt-to-Equity RatioN/A Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book0.89Miscellaneous Outstanding Shares48,310,000Free Float46,086,000Market Cap$60.39 million OptionableOptionable Beta-0.75 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:FLNA) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
